What is Cerus's market cap?

Cerus (CERS) has a market capitalization of $615.1M and trades on NASDAQ.

What is Cerus's revenue and profitability?

Cerus generated $197.6M in trailing twelve-month revenue with a net loss of $9.6M, representing a net margin of -9.8%. Gross margin stands at 64.0%, with free cash flow of -$1.2M. These figures are based on the Q1 2026 filing.

Who are Cerus's competitors?

Cerus's key competitors include Haemonetics Corporation, Cytosorbents Corp., AETHLON MEDICAL INC, and others. These companies compete in similar markets and product categories.

Who does Cerus partner with?

Cerus's notable partners include Fresenius Kabi AG, Porex Corporation, Purolite LLC, and others.

What subsidiaries does Cerus have?

Cerus's subsidiaries include Cerus Europe B.V., Cerus Zhongbaokang (Shandong) Biomedical Co., LTD.

Where is Cerus headquartered?

Cerus is headquartered in United States of America and employs approximately 280 people. It has been publicly traded since 1997.

Cerus

CERS

Market cap

$615.13M+146%

Revenue$197.6M+1.8%

Net income-$9.6M+49.6%

Free cash flow-$1.2M-118%

EPS (diluted)-$0.05+50.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$59.9MBeat by $4.2M EPS-$0.01Beat by $0.02

Read the full report

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$62.9M

EPS estimate-$0.01

Financials

Q1 2026

Income statement

See full

Revenue$53.7M+24.1%

Operating income-$354.0K+94.0%

Net income-$1.6M+78.7%

EPS (diluted)-$0.01+75.0%

Balance sheet

See full

Cash & equivalents$27.9M+43.0%

Total debt$45.0M-43.3%

Total equity$67.6M+21.7%

Total assets$222.9M+7.8%

Cash flow

See full

Operating cash flow-$3.0M-261%

CapEx$233.0K+108%

Free cash flow-$3.3M-243%

Valuation & ratios

Valuation

See full

Market cap$615.13M+146%

Enterprise value$632.24M+101%

P/S3.1×—

Returns & leverage

See full

Return on equity-15.5%-5.6pp

Debt / equity0.7×-0.8×

Current ratio1.6×-0.7×

Competitors

By market cap

Bio-Rad Laboratories$8.5B+22.9%

Haemonetics$3.6B+1.2%

Cerus$615.1M+137%

CorMedix$596.2M-33.1%

Seres Therapeutics$47.0M-59.4%

ADV

Advanced Biomed Inc. Common Stock$23.7M+106%

Cytosorbents$22.6M-61.6%

Aethlon Medical$1.5M-42.4%

By revenue growth

CorMedix+385%

Bio-Rad Laboratories+1.9%

Cerus+1.8%

Haemonetics-2.0%

By net margin

CorMedix45.25%+58.3pp

Haemonetics13.31%—

Bio-Rad Laboratories6.52%+91.7pp

Cerus-9.75%+4.9pp

Profile

Cerus Corp is a biomedical products company that develops and commercializes the INTERCEPT Blood System, a proprietary technology designed to enhance blood safety by reducing pathogens in donated blood components. The system targets biological replication to inactivate viruses, bacteria, and parasites in platelets, plasma, and red blood cells intended for transfusion. The company's core value proposition is providing a proactive safety measure that can inactivate both known and emerging threats to the global blood supply.

Competitive position

Cerus is a leading provider of pathogen reduction technology and currently holds the only FDA-approved pathogen reduction product for platelets in the United States.

GeographiesUnited States, Europe, Middle East, Commonwealth of Independent States, Latin America, China

Customer segmentsBlood Banks, Hospitals, Government Health Agencies

Business modelDirect sales, Distributor-based sales, Government contracting, Consumable-based razor-and-blade

SuppliersContract manufacturers for disposable kits, Specialty chemical suppliers for amotosalen and amustaline, Electronic component suppliers for illuminators, Raw material suppliers for compound adsorption devices

CustomersAmerican Red Cross, Établissement Français du Sang (EFS), National Health Service Blood and Transplant (NHSBT), Transfusing hospitals and physicians

CountryUnited States of America

Listed1997

Employees280.0

CEOVivek K. Jayaraman

SectorHealthcare

IndustryMedical - Devices

Websitecerus.com

FilingsSEC EDGAR

Ask your AI about Cerus.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cerus's market cap?: Cerus (CERS) has a market capitalization of $615.1M and trades on NASDAQ.
What is Cerus's revenue and profitability?: Cerus generated $197.6M in trailing twelve-month revenue with a net loss of $9.6M, representing a net margin of -9.8%. Gross margin stands at 64.0%, with free cash flow of -$1.2M. These figures are based on the Q1 2026 filing.
Who are Cerus's competitors?: Cerus's key competitors include Haemonetics Corporation, Cytosorbents Corp., AETHLON MEDICAL INC, and others. These companies compete in similar markets and product categories.
Who does Cerus partner with?: Cerus's notable partners include Fresenius Kabi AG, Porex Corporation, Purolite LLC, and others.
What subsidiaries does Cerus have?: Cerus's subsidiaries include Cerus Europe B.V., Cerus Zhongbaokang (Shandong) Biomedical Co., LTD.
Where is Cerus headquartered?: Cerus is headquartered in United States of America and employs approximately 280 people. It has been publicly traded since 1997.